As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in ...

Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust ...

By Puyaan Singh and Kunal Das April 29 (Reuters) - Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter ...

Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key ...

Regeneron Pharmaceuticals (NASDAQ:REGN) reported what management described as a strong start to 2026, driven by growth in key ...

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition ...

We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...

April 29 (Reuters) - Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue on Wednesday, ...

One day after Roche said it was starting to establish Vabysmo as the new standard of care in age-related macular degeneration (AMD) and diabetic macular edema (DME), Regeneron clapped back with the ...

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing ...

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...

First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales(recorded by Sanofi) increased 33% ...